{
    "id": 20432,
    "cites": 31,
    "cited_by": 0,
    "reference": [
        "Althouse, B., T. Bergstrom, and C. Bergstrom (2010), A Public Choice Framework for Controlling Transmissible and Evolving Diseases, Proceedings of the National Academy of Sciences, 107, 1696-1701.",
        "Anderson R. and R. May (1991), Infectious Diseases of Humans: Dynamics and Control, Oxford: Oxford University Press.",
        "Ball F. and O. Lyne (2002), Optimal Vaccination Policies for Stochastic Epidemics among a Population of Households, Mathematical Biosciences, 177&178, 333\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c354.",
        "Becker, N. and D. Starczak (1997), Optimal Vaccination Strategies for a Community of Households, Mathematical Biosciences, 139, 117-132.",
        "Boulier, B. T. Datta, and R. Goldfarb (2007), Vaccination Externalities, The B.E. Journal of Economic Analysis & Policy 7, issue 1, article 23. http://www.bepress.com/bejeap/vol7/iss1/art23.",
        "Brito, D., E. Sheshinski, and M. Intriligator (1991), Externalities and Compulsory Vaccinations, Journal of Public Economics, 45, 69-90.",
        "Cox, D. (1958), Planning of Experiments, New York: Wiley.",
        "Fine, P. (1993), Herd Immunity: History, Theory, Practice, Epidemiological Reviews, 15, 265-302.",
        "Fine, P, K. Eames, and D. Heymann (2011), &apos;Herd Immunity&apos;: A Rough Guide, Clinical Infectious Diseases, 52, 911\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c916.",
        "Hill, A. and I. Longini (2003), The Critical Vaccination Fraction for Heterogeneous Epidemic Models, Mathematical Biosciences, 181, 85\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c106.",
        "Hudgens, M. and E. Halloran (2008), Toward Causal Inference with Interference, Journal of the American Statistical Association, 103, 832-842.",
        "Institute of Medicine, (2011), Clinical Practice Guidelines We Can Trust, Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Board on Health Care Services; editors, R. Graham et al. Washington, DC: National Academies Press.",
        "Keeling, M. and A. Shattock (2012), Optimal but Unequitable Prophylactic Distribution of Vaccine, Epidemics, 4, 75-85.",
        "Loeb, M., M. Russell, L. Moss, K. Fonseca, J. Fox, D. Earn, F. Aoki, G. Horsman, P. Van Caeseele, K. Chokani, M. Vooght, L. Babiuk, R. Webby, and S. Walter (2010), Effect of Influenza Vaccination of Children on Infection Rates in Hutterite Communities: A Randomized Trial, Journal of the American Medical Association, 303, 943-950.",
        "Manski, C. (1997), Monotone Treatment Response, Econometrica, 65, 1311-1334.",
        "Manski, C. (2007), Identification for Prediction and Decision, Cambridge, MA: Harvard University Press.",
        "Manski, C. (2009), Diversified Treatment under Ambiguity, International Economic Review, 50, 10131041.",
        "Manski, C. (2010), Vaccination with Partial Knowledge of External Effectiveness, Proceedings of the National Academy of Sciences, 107, 3953-3960.",
        "Manski, C. (2011),ChoosingTreatment Policies under Ambiguity, Annual Review of Economics, 3, 25-49.",
        "Manski, C. (2013a), Identification of Treatment Response with Social Interactions, The Econometrics Journal, 16, S1-S23.",
        "Mishra, R., E. Oviedo-Orta, P. Prachi, R. Rappuoli and F. Bagnoli (2012), Vaccines and Antibiotic Resistance, Current Opinion in Microbiology, 15, 596-602.",
        "Patel, R., I. Longini, and E. Halloran (2005), Finding Optimal Vaccination Strategies for Pandemic Influenza Using Genetic Algorithms, Journal of Theoretical Biology, 234, 201-212.",
        "Rubin, D. (1978), Bayesian Inference for Causal Effects: The Role of Randomization, Annals of Statistics, 6, 34-58.",
        "Scuffham, P. and P. West (2002), Economic Evaluation of Strategies for the Control and Management of Influenza in Europe, Vaccine, 20, 2562\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2578.",
        "Tanner, M., L. Sattenspiel, and L. Ntaimo (2008), Finding Optimal Vaccination Strategies under Parameter Uncertainty Using Stochastic Programming, Mathematical Biosciences, 215, 144-151.",
        "U. S. Congress (2012), Food and Drug Administration Safety and Innovation Act, Public Law 112\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c144, 112th Congress, Washington, DC: Government Printing Office.",
        "U. S. Food and Drug Administration (1994), Summary for Basis of Approval Reference Number: 93-0395 Merck and Co. Varicella Virus Vaccine Live VARIVAX, www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm142826.pdf, accessed August 3, 2014.",
        "U. S. Food and Drug Administration (2009), Vaccine Product Approval Process, www.fda.gov/biologicsbloodvaccines/developmentapprovalprocess/biologicslicenseapplicationsblaproce ss/ucm133096.htm, accessed August 3, 2014.",
        "U. S. Food and Drug Administration (2013), Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision-Making, Draft PDUFA V Implementation Plan, patientnetwork.fda.gov/sites/default/files/fda_benefit-risk_draft_plan_final_for_posting.pdf,accessedAugust 3, 2014.",
        "Washington State Board of Health (2006), Immunization Advisory Committee: Criteria for Reviewing Antigens for Potential Inclusion in Wac 246-100-166, sboh.wa.gov/Portals/7/Doc/immunizations/FinalRecs_2006-06-14.pdf, accessed August 4, 2014.",
        "Weycker, D., J. Edelsberg, E. Halloran, I. Longini, A. Nizam, A. Ciuryla, and G. Oster (2005), Populationwide Benefits of Routine Vaccination of Children Against Influenza, Vaccine, 23, 1284-1293."
    ]
}